Aclaris Therapeutics, Inc. (ACRS) is a publicly traded Healthcare sector company. As of October 27, 2026, ACRS trades at $3.53 with a market cap of $552.00M and a P/E ratio of -6.46. ACRS moved -6.83% today. Year to date, ACRS is +31.60%; over the trailing twelve months it is +76.28%. Its 52-week range spans $1.05 to $6.60. Analyst consensus is strong buy with an average price target of $12.00. Rallies surfaces ACRS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies AI research for ACRS combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
| Metric | Value |
|---|---|
| Price | $3.53 |
| Market Cap | $552.00M |
| P/E Ratio | -6.46 |
| EPS | $-0.58 |
| Dividend Yield | 0.00% |
| 52-Week High | $6.60 |
| 52-Week Low | $1.05 |
| Volume | 342.19K |
| Avg Volume | 0 |
| Revenue (TTM) | $8.22M |
| Net Income | $-75.74M |
| Gross Margin | 79.52% |
5 analysts cover ACRS: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $12.00.